Press Releases

Cedars Sinai enrolls first patient in a study that uses AlloSure to characterize patient response to therapy BRISBANE, Calif. , March 13, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

Alongside AlloSure Heart Validation, CareDx advances SHORE enrollment    BRISBANE, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

AlloSure launch momentum drives 88% fourth quarter revenue growth BRISBANE, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic

CMS initiative “Patients over Paperwork” aims to increase organ availability BRISBANE, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

BRISBANE, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,

New data highlights the value of AlloSure to detect rejection in one of the most complex transplanted organs BRISBANE, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

AlloSure highlighted at Cutting Edge in Transplantation conference in multiple sessions BRISBANE, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated,

BRISBANE, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release

BRISBANE, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,

AlloSure utility studied in patients with delayed graft function BRISBANE, Calif. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic